Recent news highlights include a 25% increase in preliminary FY25 revenue and the company outlining its growth strategy amid challenges.

• QHSLab reported a 25% increase in preliminary FY25 revenue, indicating growth momentum in its core business [N2].
• The company outlined its growth strategy focusing on expanding adoption among independent primary care practices and addressing operational challenges [N1].

QHSLab’s integrated platform addresses growing demand for population health management and non-face-to-face clinical services, particularly in behavioral health and allergy care. Increasing reimbursement for digital assessments and care management supports revenue growth potential. The company’s recent 25% increase in preliminary FY25 revenue and improved gross margins indicate operational progress. Expansion into additional clinical domains and strategic partnerships could broaden the platform’s applicability and revenue streams. The capital-efficient sales strategy targeting independent primary care practices may facilitate scalable adoption. The company’s ability to generate positive cash flow from operations in recent years reflects improving financial discipline.

QHSLab operates in a highly competitive and rapidly evolving market with competitors possessing greater financial, technical, and marketing resources. The company’s history of net losses and reliance on debt and equity financing raise concerns about sustainability and growth capacity. Regulatory compliance risks in healthcare technology and billing are significant and may impose operational burdens. Dependence on third-party suppliers for allergy diagnostic products introduces supply chain risks. Internal control weaknesses and limited management resources may affect financial reporting and operational execution. The company’s ability to maintain profitability and continue as a going concern is uncertain, with potential dilution risks from future financing.

QHSLab’s moat is based on its integrated digital health platform that extends primary care workflows to include behavioral health and allergy diagnostics, addressing underdiagnosed conditions in a scalable manner. The combination of a modular, extensible platform with complementary allergy diagnostic products and services creates a synergistic offering tailored to independent primary care practices. The company’s focused sales approach and capital-efficient model aim to reduce implementation complexity and sales cycle duration. However, the company faces intense competition from better-resourced digital health vendors and allergy diagnostic manufacturers. Its reliance on third-party suppliers for allergy products and the evolving regulatory environment also present challenges to maintaining competitive advantage. Intellectual property protection is limited, with reliance primarily on proprietary information secrecy.

• Sustainability of Profitability and Going Concern: Although QHSLab reported net income in 2025, it has a history of net losses and uncertainty remains about its ability to sustain profitability and continue as a going concern. The company depends on additional financing to support operations and growth.
• Regulatory Compliance: The company operates in a heavily regulated healthcare environment with complex laws governing billing, privacy, and medical device regulations. Non-compliance could result in investigations, penalties, and operational disruptions.
• Competition: QHSLab faces intense competition from digital health vendors and allergy diagnostic manufacturers with greater financial and technical resources, which may limit market share and growth.
• Dependence on Third-Party Suppliers: The company relies on third parties for allergy diagnostic products, and any disruption in supply could materially adversely affect business operations and financial results.
• Internal Controls and Management Resources: Material weaknesses in internal controls and limited management staff may impair financial reporting accuracy and operational effectiveness, potentially affecting investor confidence and capital raising.

• QHSLab, Inc. is a digital health company focused on enabling independent primary care practices to identify, document, and manage underdiagnosed and undertreated behavioral health conditions through workflow-integrated digital screening and non-face-to-face follow-up care [S1].
• The company’s digital platform supports population-based screening, patient education, and follow-up care management activities outside traditional office visits [S1].
• Revenue is primarily generated through recurring per-patient, per-month subscription and service fees paid by participating medical practices for platform access and associated services [S1].
• The platform supports reimbursable clinical activities including digital assessments, asynchronous interactions, and care management services, which practices bill to payers [S1].
• QHSLab offers an allergy diagnostics and treatment service line under the AllergiEnd® brand, designed to enable primary care practices to identify and manage allergic diseases within the primary care setting [S1].
• The digital platform is modular and extensible, with core capabilities such as adaptive digital health assessments, risk identification, imminent risk alerts, automated report generation, EHR integration, and ongoing digital follow-up [S1].
• The care model facilitates a repeatable patient journey including screening, stratification, escalation, documentation, dashboarding, and reimbursement workflows [S1].
• Target customers are independent, physician-led primary care practices typically with 1-10 providers, controlling their own workflows and billing Medicare and/or commercial insurance [S1].
• Sales strategy focuses on capital-efficient, focused sales with short sales cycles, leveraging existing relationships and referrals [S1].
• The company competes with various digital health vendors, behavioral health platforms, chronic care management software, EHR tools, and allergy diagnostic device manufacturers, many with greater resources [S1].
• Near-term growth strategy emphasizes expanding adoption among independent primary care practices, increasing patient enrollment per practice, and supporting recurring revenue growth through sustained patient engagement [S1].
• Longer-term growth opportunities may include expansion into additional clinical domains, deeper workflow integration, and broader strategic partnerships, subject to capital and regulatory considerations [S1].
• QHSLab had 12 full-time employees as of March 30, 2026, focused on sales and operations, supplemented by consultants for programming, quality, marketing, and medical advisory services [S1].
• The company reported net income of $457,417 for the year ended December 31, 2025, partly due to a gain on extinguishment of debt of approximately $666,000 [S1].
• Revenues were $2,691,741 in 2025 and $2,131,926 in 2024, with gross margins improving from 63.7% to 67.3% [S1].
• Liquidity as of December 31, 2025 included $636,157 in cash and equivalents, current assets of $883,009, current liabilities of $449,860, with a current ratio of 1.96 and cash ratio of 1.41 [S1].
• The company has a history of net losses prior to 2025 and faces uncertainty about sustaining profitability and continuing as a going concern [S1].
• QHSLab depends on additional financing to grow and has outstanding notes and loans totaling approximately $201,788 as of December 31, 2025 [S1].
• Risks include regulatory compliance in a heavily regulated healthcare environment, competition from better-resourced companies, dependence on third-party suppliers for allergy products, and internal control weaknesses [S1].
• Recent news highlights a 25% increase in preliminary FY25 revenue and outlines a growth strategy amid challenges [N2][N1].